ABL Stock Chart & Stats
€81.88
-€0.02(-0.02%)
At close: 4:00 PM EST
€81.88
-€0.02(-0.02%)
Day’s Range― - ―
52-Week Range€70.10 - €116.56
Previous CloseN/A
Volume11.00
Average Volume (3M)1.28K
Market Cap
€157.80B
Enterprise Value€206.76K
Total Cash (Recent Filing)€7.29B
Total Debt (Recent Filing)€34.05B
Price to Earnings (P/E)33.2
Beta0.25
Next Earnings
Oct 21, 2026EPS Estimate
1.24Next Dividend Ex-DateN/A
Dividend Yield2.33%
Share Statistics
EPS (TTM)3.60
Shares Outstanding1,741,812,400
10 Day Avg. Volume1,759
30 Day Avg. Volume1,281
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€105.18Price Target Upside28.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)4.84
Revenue Forecast (FY)€44.17B
Bulls Say, Bears Say
Bulls Say
Recurring, Diversified Revenue ModelAbbott’s portfolio spans diagnostics (razor-and-blades consumables), implantable and disposable device components, nutrition, and branded generics, creating multiple recurring revenue streams. That diversification lowers volatility, sustains installed-base driven consumable demand, and supports predictable mid-term cash flow.
Healthy Margins And Conservative LeverageSustained gross and operating margins provide structural profitability that funds R&D and commercial investment. Conservative leverage (low debt/equity) enhances balance-sheet resilience, enabling steady capital allocation to M&A, share returns, or trials without stressing solvency over the medium term.
Substantial Pipeline And Regulatory MilestonesRecent approvals, pivotal trial completions, and planned launches (Libre Duo, Amulet 360, IVL enrollment, Bolt catheter iterations) materially expand product optionality. Successful execution would drive durable revenue expansion across diagnostics, diabetes and structural heart markets over 12–24 months.
Bears Say
Weaker Cash Conversion MomentumDeclining free cash flow and operating cash flow below reported net income indicate weaker earnings quality and conversion. That constrains organic funding for investment and buybacks, increasing reliance on execution to restore cash generation and maintain capital-return flexibility long term.
China VBP-related Revenue PressureVolume-based procurement (VBP) effects in China create persistent pricing and volume pressure in a large market. Multi-year procurement and tender dynamics can suppress international diagnostics and device comparables, reducing revenue visibility and requiring sustained market-share or mix gains elsewhere.
Timing Uncertainty For Key Approvals And ReimbursementsMaterial upside from CGM reimbursement expansions or device approvals hinges on regulatory and payer decisions whose timing is uncertain. Delays or adverse determinations would postpone revenue scale and limit the realization of projected market opportunities for quarters to years.
Abbott Laboratories News
ABL FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was €70.10 and its highest was €116.56 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is €157.80B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Oct 21, 2026 which is in 87 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Jul 16, 2026. The company reported €1.151 earnings per share for the quarter, beating the consensus estimate of €1.122 by €0.029.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of €0.554 which represents an annual dividend yield of 2.33%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.24.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,741,812,400 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of €1.151 in its last earnings report, beating expectations of €1.122. Following the earnings report the stock price went up 10.254%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in DE:ABL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Company Description
Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
ABL Company Deck
ABL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall, the call conveyed constructive momentum across Abbott’s diversified portfolio with multiple product and regulatory milestones, gross margin expansion, and raised EPS guidance. Key growth engines — diagnostics (notably cancer testing), nutrition recovery, devices (EP, rhythm management, heart failure) and diabetes/CGM — provide visibility to second-half acceleration. Offsetting risks include a soft respiratory season hurting rapid/molecular diagnostics, China VBP headwinds, structural heart US commercial execution needs, and uncertainty/timing around reimbursement and regulatory approvals for some high-impact products (e.g., CGM reimbursement expansion, Libre Duo FDA clearance). On balance, highlights notably outweigh the lowlights, with achievable near-term drivers and a clear pipeline cadence underpinning positive momentum.View all DE:ABL earnings summariesABL Net sales Breakdown
12.49% Established Pharmaceutical Products
19.06% Nutritional Products
20.16% Diagnostic Products
48.25% Medical Devices
0.04% Other

ABL Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€105.18
▲(28.45% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










